BeOne Medicines (NASDAQ:ONC) Stock Price Expected to Rise, Citizens Jmp Analyst Says

BeOne Medicines (NASDAQ:ONC) had its price objective raised by stock analysts at Citizens Jmp from $396.00 to $405.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage currently has a “market outperform” rating on the stock. Citizens Jmp’s price target points to a potential upside of 16.29% from the stock’s previous close.

ONC has been the subject of a number of other research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of BeOne Medicines in a research report on Friday, July 17th. JPMorgan Chase & Co. lifted their price objective on shares of BeOne Medicines from $415.00 to $425.00 and gave the stock an “overweight” rating in a research note on Thursday, July 23rd. Zacks Research downgraded shares of BeOne Medicines from a “strong-buy” rating to a “hold” rating in a report on Friday, July 3rd. Barclays increased their target price on shares of BeOne Medicines from $403.00 to $407.00 and gave the stock an “overweight” rating in a research report on Thursday. Finally, Truist Financial raised their target price on shares of BeOne Medicines from $413.00 to $416.00 and gave the stock a “buy” rating in a report on Tuesday, July 7th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $400.00.

BeOne Medicines Stock Performance

NASDAQ:ONC opened at $348.27 on Thursday. The stock has a market cap of $38.21 billion, a P/E ratio of 61.32 and a beta of 0.49. The stock has a 50 day simple moving average of $296.52 and a 200 day simple moving average of $308.89. The company has a current ratio of 3.40, a quick ratio of 3.27 and a debt-to-equity ratio of 0.17. BeOne Medicines has a 1-year low of $253.95 and a 1-year high of $385.22.

BeOne Medicines (NASDAQ:ONC) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $2.05 EPS for the quarter, beating analysts’ consensus estimates of $1.40 by $0.65. The firm had revenue of $1.71 billion for the quarter, compared to analyst estimates of $1.66 billion. BeOne Medicines had a return on equity of 14.23% and a net margin of 10.70%. Research analysts anticipate that BeOne Medicines will post 6.26 earnings per share for the current year.

Insider Buying and Selling

In related news, SVP Chan Henry Lee sold 1,044 shares of the business’s stock in a transaction dated Thursday, July 30th. The stock was sold at an average price of $323.69, for a total value of $337,932.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Aaron Rosenberg sold 1,157 shares of the company’s stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $312.71, for a total transaction of $361,805.47. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 345,561 shares of company stock valued at $105,625,947. Company insiders own 6.19% of the company’s stock.

Hedge Funds Weigh In On BeOne Medicines

Several hedge funds have recently bought and sold shares of the company. Mariner LLC lifted its holdings in shares of BeOne Medicines by 3.8% during the 4th quarter. Mariner LLC now owns 883 shares of the company’s stock worth $269,000 after acquiring an additional 32 shares during the period. Signaturefd LLC boosted its position in shares of BeOne Medicines by 10.7% during the 4th quarter. Signaturefd LLC now owns 340 shares of the company’s stock worth $103,000 after acquiring an additional 33 shares in the last quarter. Farther Finance Advisors LLC increased its stake in BeOne Medicines by 21.8% in the fourth quarter. Farther Finance Advisors LLC now owns 218 shares of the company’s stock valued at $66,000 after acquiring an additional 39 shares during the last quarter. CWM LLC increased its stake in BeOne Medicines by 32.8% in the fourth quarter. CWM LLC now owns 158 shares of the company’s stock valued at $48,000 after acquiring an additional 39 shares during the last quarter. Finally, Steadtrust LLC increased its stake in BeOne Medicines by 3.7% in the second quarter. Steadtrust LLC now owns 1,400 shares of the company’s stock valued at $399,000 after acquiring an additional 50 shares during the last quarter. 48.55% of the stock is owned by institutional investors.

Trending Headlines about BeOne Medicines

Here are the key news stories impacting BeOne Medicines this week:

• Positive Sentiment: Strong Q2 performance: BeOne reported adjusted earnings of $2.05 per share, topping the $1.40 consensus estimate, while revenue reached $1.71 billion versus expectations of $1.66 billion. The earnings beat reinforces confidence in the company’s oncology portfolio and profitability. BeOne Medicines Q2 earnings report
• Positive Sentiment: 2026 outlook raised: Management increased its full-year revenue forecast to approximately $6.6 billion-$6.8 billion, above Wall Street’s prior estimate of $6.5 billion, citing a 30% quarterly revenue surge. BeOne Medicines raises 2026 outlook
• Positive Sentiment: Analyst targets moved higher: TD Cowen raised its target to $454 and assigned a Buy rating; Guggenheim increased its target to $430, Truist lifted its target to $418, and Citizens JMP raised its target to $405. RBC made a modest reduction to $450 but retained an Outperform rating. Collectively, the updates indicate substantial implied upside from recent trading levels. Analyst price-target updates
• Positive Sentiment: Institutional buying: Bank of America, Man Group, BNP Paribas and other institutions recently established or expanded positions, suggesting continued professional-investor interest in ONC.
• Neutral Sentiment: Insider sale was tax-related: CFO Aaron Rosenberg sold 1,157 shares valued at about $362,000 to cover tax withholding from vested equity awards. The transaction is therefore a limited bearish signal. SEC insider transaction filing
• Negative Sentiment: Valuation risk: With a high earnings multiple and the stock trading below its 52-week high, investors may require continued rapid growth and execution to justify the current valuation.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.